Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Neurological soft-sign abnormalities have been implicated in obsessive-compulsive disorder (OCD). This first comprehensive data analysis evaluated the association between baseline neurological soft signs and treatment response in 117 OCD patients treated with controlled-release fluvoxamine in a double-blind placebo-controlled trial. Total and right-sided soft signs for the responders and the nonresponders did not differ significantly. Left-sided visuospatial soft signs were significantly increased in treatment nonresponders compared to responders. These subtle neurological abnormalities may implicate a potential subgroup of OCD patients with poorer treatment response. This may have treatment implications and therefore serve as a screening tool in OCD.
Hollander
Eric
E
Mt. Sinai School of Medicine, One Gustave Levy Place, Box 1230, NY, NY 10029, USA. Eric.Hollander@mssm.edu
Kaplan
Alicia
A
Schmeidler
James
J
Yang
Haichen
H
Li
David
D
Koran
Lorrin M
LM
Barbato
Luigi M
LM
D004311:Double-Blind Method; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D010555:Personality Inventory / Q000706:statistics & numerical data; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors